Steven Foung

Publication Details

  • SEROLOGIC CONFIRMATION OF SIMIAN T-LYMPHOTROPIC VIRUS TYPE-I INFECTION BY USING IMMUNOASSAYS DEVELOPED FOR HUMAN T-LYMPHOTROPIC VIRUS-ANTIBODY DETECTION JOURNAL OF CLINICAL MICROBIOLOGY Rudolph, D. L., Yee, J., Mone, J., Foung, S. K., LIPKA, J. J., Reyes, G. R., Hadlock, K., Chan, L., Villinger, F., Lairmore, M. D., Sinha, S., Lal, R. B. 1992; 30 (4): 858-861

    Abstract:

    Serum specimens from diverse species of Old World monkeys, categorized as seropositive (n = 97) or seronegative (n = 23) for human T-lymphotropic virus (HTLV) infection, were tested by using recombinant env-spiked Western immunoblot assays and synthetic peptide assays for simultaneous detection and discrimination of simian T-lymphotropic virus (STLV) infection. Of the 97 seropositive specimens, 93 reacted with the recombinant transmembrane (r21env) protein and 90 reacted with a recombinant, MTA-1, derived from the central region of the external glycoprotein of HTLV-I (rgp46env), thus yielding test sensitivities of 96 and 93%, respectively. While 1 of the 23 negative monkey specimens reacted with r21env, none reacted with rgp46env, for overall specificities of 96 and 100%, respectively. Analysis of synthetic peptide-based immunoassays demonstrated that while 85 of 97 (88%) seropositive specimens reacted with HTLV-I-specific epitope (p19gag), none of the specimens reacted with HTLV-II-specific epitope (gp52env). These results show that recombinant envelope-spiked Western blots provide a simple means for serologic confirmation of STLV-I infection and that type-specific synthetic peptides can be used to confirm the virus type in seropositive monkey specimens.

    View details for Web of Science ID A1992HJ48700018

    View details for PubMedID 1349306

Stanford Medicine Resources:

Footer Links: